The healthcare communications agency Discovery Worldwide announced the appointment of Matt Silver to SVP, Strategy, Engagement and Analytics.
Teva revenues in the first quarter of 2017 were $5.6 billion, up 17% compared to the first quarter of 2016, primarily due to the inclusion of the Actavis Generics business, following the closing of the acquisition on August 2, 2016. Excluding the impact of foreign exchange fluctuations, revenues increased 22%.
The European Commission approved Merck’s anti-PD-1 therapy Keytruda for treating adult patients with relapsed or refractory classical Hodgkin lymphoma.
Scout, a specialty pharmaceutical advertising agency, has been acquired by a private equity fund. The agency was picked up by Stagwell Media LLC, the fund of the Stagewell Group.
Klick Health announced several senior-level creative, medical strategy and client service executives have joined the independent agency.
eHealth Inc., which operates eHealth.com – the nation’s first and largest private online health insurance exchange – has released its Health Insurance Price Index Report for the 2017 Open Enrollment Period. The report shows that monthly premiums for plans selected on eHealth.com by unsubsidized shoppers averaged $378 for individuals and $997 for families of two or more.
Pfizer Inc. announced that the United States Food and Drug Administration accepted for review the supplemental New Drug Application for Xeljanz (tofacitinib citrate) 5 mg twice daily for the treatment of adult patients with active psoriatic arthritis (PsA). A separate sNDA was also accepted for Xeljanz extended release 11 mg once daily use in PsA.
Healthcare and pharma agency HYC Health has hired Shannon Carlson as senior VP, account director. She began her new role May 1 and reports to Managing Director Susan Flinn Cobian.
PerkinElmer Inc., a global leader committed to innovating for a healthier world, announced that the company has completed the sale of its Medical Imaging business to Varex Imaging Corporation.
Caribou Biosciences Inc. announced the Nature Methods publication describing SITE-Seq, a new method for comprehensively mapping CRISPR-Cas9 cleavage sites across the genome of any organism. When compared against other off-target analysis techniques, SITE-Seq detected potential off-target cleavage sites with a higher degree of resolution.
